Novel concentration-QTc models for early clinical studies with parallel placebo controls: A simulation study

Area of Science:

• Pharmacology and Toxicology
• Clinical Trial Design
• Biostatistics

Background:

• The QTc interval is a key biomarker for drug-induced cardiac toxicity.
• ICH E14 guideline Q&As provide alternatives to thorough QT studies for early drug development.
• Evaluating concentration-QTc relationships is crucial for assessing cardiac safety.

Purpose of the Study:

• To propose novel statistical models for analyzing concentration-QTc relationships in early clinical studies.
• To specifically address the two-day covariance structure of QTc intervals in baseline and dosing days.
• To offer flexible modeling approaches for various study designs, including single and multiple ascending dose studies.

Main Methods:

• Development of a two-day QTc model using constrained longitudinal data analysis and mixed-effects modeling.
• Incorporation of variance components to capture complex two-day covariance structures.
• Proposal of a one-day QTc model and models for multiple ascending dose studies.

Main Results:

• The proposed models demonstrated effective control of the false negative rate for cardiotoxic drugs.
• Improved accuracy and statistical power were observed for identifying non-toxic drugs compared to existing models.
• The models successfully captured the two-day covariance structure in simulations.

Conclusions:

• The developed QTc models offer a robust and accurate method for early assessment of drug-induced cardiac safety.
• These models support regulatory guidelines by providing reliable concentration-QTc relationship evaluations.
• Implementation of these models can lead to more efficient and informed drug development decisions regarding cardiac risk.